

# Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes

HIROFUMI MAKINO, MD<sup>1</sup>  
MASAKAZU HANEDA, MD<sup>2</sup>  
TETSUYA BABAZONO, MD<sup>3</sup>  
TATSUMI MORIYA, MD<sup>4</sup>  
SADAYOSHI ITO, MD<sup>5</sup>

YASUHIKO IWAMOTO, MD<sup>6</sup>  
RYUZO KAWAMORI, MD<sup>7</sup>  
MASAHIRO TAKEUCHI, SCD, MPH<sup>8</sup>  
SHIGEHIRO KATAYAMA, MD<sup>9</sup>  
FOR THE INNOVATION STUDY GROUP

To date, evidence for long-term renoprotection with angiotensin receptor blockers (ARBs) has come almost exclusively from Caucasian patients (1–3), despite Japanese people being at high risk of diabetic nephropathy and very susceptible to end-stage renal disease (4–6). We conducted the INNOVATION Study (Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy) to evaluate the efficacy of an ARB in preventing transition from microalbuminuria to overt nephropathy in Japanese patients (7). This study is the first large-scale clinical study to investigate prevention of overt diabetic nephropathy using an ARB in normotensive and hypertensive Japanese patients with type 2 diabetes.

## RESEARCH DESIGN AND METHODS

The randomized, multicenter, double-blind, placebo-controlled trial was performed in patients aged from 30 to 74 years with type 2 diabetes and urinary albumin-to-creatinine ratio (UACR) 100–300 mg/g and serum

creatinine <1.5 mg/dl (men) and <1.3 mg/dl (women). Exclusion criteria included type 1 diabetes, age of diabetes onset <30 years, seated systolic blood pressure (SBP)/diastolic blood pressure (DBP)  $\geq$ 180/100 mmHg, and definable chronic kidney disease other than diabetic nephropathy. A total of 527 patients out of 1,855 screened were randomized to 80 or 40 mg telmisartan or placebo; the starting dose was 20 mg, titrated to 40 mg after 2 weeks or to 80 mg after a further 2 weeks. Minimum treatment period was 1 year for each patient. Primary efficacy end point was the transition rate from incipient to overt nephropathy (UACR >300 mg/g and increase  $\geq$ 30% from baseline at two consecutive 4-week visits). Secondary end point was microalbuminuria remission (UACR <30 mg/g). Frequency and severity of adverse events were also assessed. The Kaplan-Meier method was used to determine transition rates to overt nephropathy; log-rank test was used for pairwise comparison between treatment groups. Effect of blood pressure reduction on transition rate was estimated us-

ing Cox's proportional hazard model. The protocol conformed to the principles of the Declaration of Helsinki and was approved by the institutional review boards at the 142 study centers (7). Patients provided written informed consent before enrollment.

**RESULTS**— Of the 527 randomized patients (mean age 61.7 years), 13 were excluded from primary analysis because of suspected type 1 diabetes or UACR measurements being missing during treatment. Mean duration of follow-up was  $1.3 \pm 0.5$  years (maximum 2.3 years). Transition rates to overt nephropathy were 80 mg telmisartan ( $n = 168$ ) 16.7%, 40 mg telmisartan ( $n = 172$ ) 22.6%, and placebo ( $n = 174$ ) 49.9% (both telmisartan doses vs. placebo,  $P < 0.0001$ ) (Fig. 1A). In addition, 163 normotensive patients were included in the study. Transition rates in normotensive patients were 80 mg telmisartan ( $n = 51$ ) 11.0%, 40 mg telmisartan ( $n = 58$ ) 21.0%, and placebo ( $n = 54$ ) 44.2% (both telmisartan doses vs. placebo,  $P < 0.01$ ) (Fig. 1B). After adjustment for changes in SBP, telmisartan still decreased the transition rate to overt nephropathy. Telmisartan (80 and 40 mg) reduced mean UACR at final observation by 58.8 and 37.9 mg/g, respectively, and placebo increased UACR by 40.9 mg/g (both telmisartan doses vs. placebo,  $P < 0.0001$ ). Microalbuminuria remission at final observation occurred in 21.2% with 80 mg telmisartan, 12.8% with 40 mg telmisartan, and 1.2% with placebo (both telmisartan doses vs. placebo,  $P < 0.001$ ). One or more adverse event was recorded in >90% of patients in each treatment group; most events were mild or moderate in intensity. Regarding the decrease of blood pressure, SBP/DBP fell from 138/78 mmHg to 128/72 mmHg with 80 mg telmisartan, from 137/78 mmHg to 128/72 mmHg with 40 mg telmisartan, and from 137/77 mmHg to 132/74 mmHg with placebo (each blood pressure change at 1 year from baseline  $P < 0.01$ ).

**CONCLUSIONS**— Patients with type 2 diabetes and microalbuminuria receiving

From the <sup>1</sup>Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan; the <sup>2</sup>Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Hokkaido, Japan; the <sup>3</sup>Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan; the <sup>4</sup>Department of Endocrinology, Diabetes, and Metabolism, Kitasato University School of Medicine, Kanagawa, Japan; the <sup>5</sup>Division of Nephrology, Tohoku University Graduate Medical School, Miyagi, Japan; the <sup>6</sup>Department of Medicine, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan; the <sup>7</sup>Department of Medicine, Medical School, Juntendo University, Tokyo, Japan; the <sup>8</sup>Division of Biostatistics, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan; and the <sup>9</sup>Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical School, Saitama, Japan.

Address correspondence and reprint requests to Professor Hirofumi Makino, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, Japan. E-mail: makino@md.okayama-u.ac.jp.

Received for publication 21 November 2006 and accepted in revised form 5 March 2007.


Published ahead of print at <http://care.diabetesjournals.org> on 26 March 2007. DOI: 10.2337/dc06-1998. Clinical trial reg. no. NCT00153088, [clinicaltrials.gov](http://clinicaltrials.gov).

**Abbreviations:** ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure; UACR, urinary albumin-to-creatinine ratio.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.



**Figure 1**—Kaplan-Meier curves for transition from incipient to overt nephropathy in patients treated once daily with 80 mg telmisartan (T80), 40 mg telmisartan (T40), and placebo.

80 or 40 mg telmisartan achieved superior renoprotection, demonstrated by lower transition rates to overt nephropathy, compared with placebo. Achievement of microalbuminuria remission was superior with 80 or 40 mg telmisartan than with placebo. Remission is a key goal for renoprotection, as well as cardiovascular protection (8). Remission rates compare very favorably with those reported in Caucasian hypertensive patients with type 2 diabetes and microalbuminuria treated with irbesartan (3). Telmisartan also reduced transition to

overt nephropathy in normotensive patients, suggesting telmisartan had a blood pressure-independent effect. Further evidence for this is that differences in transition rates with respective treatments were maintained when adjustment was made for SBP reduction. The beneficial effects of telmisartan were dose dependent.

Overall, telmisartan reduced transition from incipient to overt nephropathy and induced remission of albuminuria in Japanese type 2 diabetic patients.

References

1. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345: 861–869, 2001
2. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345:851–860, 2001
3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345:870–878, 2001
4. Hollenberg NK: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. *Curr Hypertens Rep* 3:177, 2001
5. US Renal Data System: *USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*. Available from [http://www.usrds.org/adr\\_2005.htm](http://www.usrds.org/adr_2005.htm)
6. Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Ohmori H, Morita O, Iseki K, Kikuchi K, Kubo K, Suzuki K, Tabei K, Fushimi K, Miwa N, Wada A, Yanai M, Akiba T: Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo: an overview of regular dialysis treatment in Japan (as of December 31, 2001). *Ther Apher Dial* 8:3–32, 2004
7. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, for the Incipient to Overt; Angiotensin II-Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy Study Group: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy: rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. *J Int Med Res* 33:677–686, 2005
8. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. *Lancet* 357:1601–1608, 2001